Enzo Biochem to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum


Enzo Biochem, Inc.

NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ), a leading bioscience and diagnostics company, today announced that management will present at KeyBanc Capital Markets Life Sciences and Medtech Investor Forum, on Tuesday, March 22, 2022 at 3:00 p.m. EST. The format will be a “fireside chat” moderated by KeyBanc research analyst Paul Knight.

Hamid Erfanian, Chief Executive Officer and David Bench, Chief Financial Officer, will host virtual 1×1 meetings on March 22. If you would like to arrange a one-on-one meeting, please contact your KeyBanc representative.

A webcast of the presentation can be followed live via the following link:
Webcast presentation link – Click here or please visit the “Upcoming Events” section of the “Investor Information” page of Enzo Biochem’s website at www.enzo.com

About KeyBanc Capital Markets

KeyBanc Capital Markets has over $50 billion in capital committed to clients and an award-winning equity research team that provides coverage on over 600 publicly traded companies. Our clients benefit from our deep expertise in seven targeted industry sectors, including consumer and retail, healthcare, industrial, public sector, real estate and technology. KeyBanc Capital Markets is a trade name under which are marketed the corporate and investment banking products and services of KeyCorp and its subsidiaries, KeyBanc Capital Markets Inc., member FINRA/SIPC and KeyBank National Association (“KeyBank NA”).

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that offer many advantages over previous standards. A global company, Enzo Biochem uses cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing healthcare needs of today and tomorrow. Enzo Biochem’s products and technologies are supported by a broad and deep intellectual property portfolio, with patent coverage on a number of key enabling technologies.
For more information, please visit www.Enzo.com or follow Enzo Biochem on Twitter and

Forward-looking statements

Except for historical information, the matters discussed in this release may be deemed “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding the intention, belief or current expectations of the Company and its management, including those relating to cash flow, gross margins, revenues and expenses which depend on a number of factors beyond the Company’s control, including, but not limited to, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation and general trade conditions. See the risk factors in the company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. . The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


Contact Enzo Biochem

For: Enzo Biochem:

David Banc, Chief Financial Officer
[email protected]

For the media:

Lynn Granito
Berry & Company Public Relations
[email protected]

For investors:

Bob Yedid
LifeSci Advisors, LLC
[email protected]


Comments are closed.